Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

Specimen Handling 2nedaplatin 1X-Rays 1Relaxation Therapy 1Protons 1Proton Therapy 1Platinum Compounds 1Physical Therapy Modalities 1Pemetrexed 1Paclitaxel 1Docetaxel 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Resectable Lung Non-Small Cell Carcinoma × Clear all
NCT07584239 2026-05-26

Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial

Ohio State University Comprehensive Cancer Center

Phase NA Recruiting
30 enrolled

Resectable Lung Non-Small Cell Carcinoma

NCT06008730 2025-11-10

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

Emory University

Phase 2 Recruiting
20 enrolled

Resectable Lung Non-Small Cell Carcinoma

NCT06775275 2025-01-15

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
60 enrolled

Resectable Lung Non-Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡